<?xml version="1.0" encoding="UTF-8"?><safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-38</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry/>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150222</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150206</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>Literature</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb/>
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-38</companynumb>
		<duplicate/>
		<casenullification/>
		<nullificationreason/>
		<medicallyconfirm/>
		<primarysource>
			<reportertitle/>
			<reportergivename>E</reportergivename>
			<reportermiddlename/>
			<reporterfamilyname>Nanishi</reporterfamilyname>
			<reporterorganization/>
			<reporterdepartment/>
			<reporterstreet/>
			<reportercity/>
			<reporterstate/>
			<reporterpostcode/>
			<reportercountry>JP</reportercountry>
			<qualification>3</qualification>
			<literaturereference>Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection. 2015;48:109-112</literaturereference>
			<studyname/>
			<sponsorstudynumb/>
			<observestudytype/>
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename/>
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate/>
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype/>
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment/>
			<receivertitle/>
			<receivergivename/>
			<receivermiddlename/>
			<receiverfamilyname/>
			<receiverstreetaddress/>
			<receivercity/>
			<receiverstate/>
			<receiverpostcode/>
			<receivercountrycode/>
			<receivertel/>
			<receivertelextension/>
			<receivertelcountrycode/>
			<receiverfax/>
			<receiverfaxextension/>
			<receiverfaxcountrycode/>
			<receiveremailaddress/>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientgpmedicalrecordnumb/>
			<patientspecialistrecordnumb/>
			<patienthospitalrecordnumb/>
			<patientinvestigationnumb/>
			<patientbirthdateformat/>
			<patientbirthdate/>
			<patientonsetage/>
			<patientonsetageunit/>
			<gestationperiod/>
			<gestationperiodunit/>
			<patientagegroup/>
			<patientweight/>
			<patientheight/>
			<patientsex/>
			<lastmenstrualdateformat/>
			<patientlastmenstrualdate/>
			<patientmedicalhistorytext/>
			<resultstestsprocedures>soluble interleukin-2 receptor was 6061 U/mL</resultstestsprocedures>
			<reaction>
				<primarysourcereaction>DRESS syndrome</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10058899</reactionmeddrallt>
				<reactionmeddraversionpt/>
				<reactionmeddrapt/>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat/>
				<reactionstartdate/>
				<reactionenddateformat/>
				<reactionenddate/>
				<reactionduration/>
				<reactiondurationunit/>
				<reactionfirsttime/>
				<reactionfirsttimeunit/>
				<reactionlasttime/>
				<reactionlasttimeunit/>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Alanine aminotransferase</testname>
				<testresult>1777</testresult>
				<testunit>U/L</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Aspartate aminotransferase</testname>
				<testresult>1821</testresult>
				<testunit>U/L</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Aspartate aminotransferase</testname>
				<testresult>894</testresult>
				<testunit>U/L</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Bilirubin direct</testname>
				<testresult>5.1</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Bilirubin direct</testname>
				<testresult>5.6</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Bilirubin total</testname>
				<testresult>6.8</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Bilirubin total</testname>
				<testresult>7.8</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Immunoglobulin E</testname>
				<testresult/>
				<testunit/>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Lactate dehydrogenase</testname>
				<testresult>637</testresult>
				<testunit>U/L</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Body temperature</testname>
				<testresult/>
				<testunit/>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>C-reactive protein</testname>
				<testresult>0.09</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Eosinophils</testname>
				<testresult>4</testresult>
				<testunit>%</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>GGTP</testname>
				<testresult>348</testresult>
				<testunit>U/L</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Hemoglobin</testname>
				<testresult>11.7</testresult>
				<testunit>g/dL</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Lymphocytes</testname>
				<testresult>55</testresult>
				<testunit>%</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Atypical lymphocytes</testname>
				<testresult>5</testresult>
				<testunit>%</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Monocytes</testname>
				<testresult>10</testresult>
				<testunit>%</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Segmented neutrophil count</testname>
				<testresult>26</testresult>
				<testunit>%</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Platelet count</testname>
				<testresult>143</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Ferritin</testname>
				<testresult>1492</testresult>
				<testunit>mg/dl</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Leucocyte count</testname>
				<testresult>3.99</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct/>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry/>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext/>
				<drugdosageform>Suppository</drugdosageform>
				<drugadministrationroute>54</drugadministrationroute>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10016558</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration/>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058899</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10058899</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct/>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry/>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext/>
				<drugdosageform/>
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10016558</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration/>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>CEFDITOREN PIVOXIL</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This case was derived from a scientific literature which describes drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection.The article describes a 4-year-old male child who was hospitalized for drug reaction with eosinophilia and systemic symptoms (DRESS) while on therapy with acetaminophen suppository and cefditoren pivoxil for fever.The child was admitted to the hospital on the fourteenth day of illness because of prolonged fever, jaundice, and generalized skin eruption. The patient had received oral cefditoren pivoxil and acetaminophen suppository from the 6th day to the 12th day of illness. Despite the defervescence on the 11th day of illness, jaundice and abdominal pain emerged. On the 13th day of illness, he presented to a practitioner again because of developing generalized skin rash. The laboratory findings showed increased levels of aspartate aminotransferase at 1821 U/L, alanine aminotransferase at 1777 U/L, total bilirubin at 6.8 mg/dL and direct bilirubin at 5.1 mg/dL. He was then referred to the reporter for further management. On admission, his body temperature was 38.0 Dec C. Skin and bulbar conjunctiva were icteric. Pruritic maculopapular eruption spread confluently on the trunk, extremities, palms, and soles. Mucous membranes and conjunctivas were spared. There was cervical lymphadenopathy, hepatomegaly, but no splenomegaly.Complete blood counts showed a leukocyte count of 3.99 X 109/L with 26% segmented neutrophils, 55% lymphocytes, 10% monocytes, 4% eosinophils, and 5% atypical lymphocytes, a hemoglobin concentration of 11.7 g/dL and a platelet count of 143 X 109/L. Blood chemistry showed total bilirubin at 7.8 mg/dL, direct bilirubin at 5.6 mg/dL, aspartate aminotransferase at 570 U/L, alanine aminotransferase at 894 U/L, lactate dehydrogenase at 637 U/L and g-glutamyl transpeptidase at 348 U/L. C-reactive protein concentration was 0.09 mg/dL. Serum levels of ferritin (1492 mg/dL) and soluble interleukin-2 receptor (6061 U/mL) were both high. Immunoglobulin levels and coagulation studies were unremarkable (immunoglobulin E was less than 10 U/mL). Surface maker analysis of the peripheral blood lymphocytes showed a reversed CD4/CD8 ratio (0.45) and a prominently increased proportion of activated CD8T cells (72.2%). There were past inactive infections, but no reactivation of Cytomegalovirus or HHV-6. Positive antiviral capsid antigen immunoglobulin M with negative anti-EBV nuclear antigen antibody indicated primary EBV infection. A high copy number of EBV-DNA (3X106 copies/L of peripheral blood) was detected by real-time polymerase chain reaction. Lymphocyte transformation test (LTT) for acetaminophen [stimulation index (SI) 555%] or cefditoren pivoxil (SI 314%) was highly positive. The diagnosis of DRESS was made because the patient fulfilled all but one criteria of eosinophilia. Dexchlorpheniramine and glycyrrhizinate were started with no use of the other drugs including antipyretics. All symptoms resolved until the cessation of therapy on the 19th day of illness. Negative LTT for acetaminophen (SI 81%) or cefditoren pivoxil (SI 71%) was confirmed 2 months later. Thereafter, skin eruption did not appear when acetaminophen was administered at the chance of fever.Author’s comment:Drug reactions in childhood are often challenging to diagnose because of accompanying viral diseases presenting cutaneous manifestation. The diagnostic criteria of DRESS/DIHS overlap the representative manifestations of infectious mononucleosis (IM). DRESS was first confirmed by the positive LTT in this pediatric patient with primary EBV infection. This observation suggests an unexpected utility of LTT for the correct diagnosis of DRESS associated with primary EBV infection. Reactivation of herpes virus infection concurrent with drug hypersensitivity is considered specific to DRESS. The patient showed slight neutropenia and thrombocytopenia, but no eosinophilia. High serum levels of soluble interleukin-2 receptor and ferritin during the acute phase indicated the excessive immune activation leading to hemophagocytic syndrome, when eosinophilia is unusual. Pituitary adrenal axis might result in the modest increase of eosinophil counts during the convalescent phase (18th day of illness: 0.29 X 109/L). Severe immune responses to the virus reactivation may explain the clinical manifestations of DRESS. The culprit drugs triggered the virus replication in EBV transformed B cells from the patient. Both LTT for acetaminophen and cefditoren pivoxil were definitely positive in the patient. These drugs are chemically different and are metabolized through different pathways. Multidrug hypersensitivity rather than the cross reaction may explain the distinct manifestation although no skin patch test was performed. In the patient, the positive result of LTT came to be negative with the favorable clinical course. The proportion of circulating T cell subsets from patients affects the in vitro result of LTT. Functional regulatory T cells at the acute stage of DRESS may serve to prevent the activation and expansion of drug-specific T cells. However, the proportion of regulatory T cells was reported to decrease in patients with primary infection, but not with reactivation of EBV. Further study is needed to determine the sensitivity of LLT during the acute and convalescent phase of primary EBV infection assessed by the analysis of functional T cell subpopulation. Sequential LLT may be useful to determine the ominous hypersensitivity to drugs in patients with the primary infection of EBV.Literary Citation:  Nanishi E, Hoshina T, Ohga S,  Nishio H,  Hara T. Drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection. Journal of Microbiology, Immunology and Infection 48; 2015: 109-112.BMS Medical Evaluation Comment :This patient was diagnosed with drug rash with eosinophilia and systemic symptoms (DRESS) while on acetaminophen and cefditoren therapy. Based on the nature of the event and considering the positive lymphocyte transformation test for acetaminophen and cefditoren, the event was considered a drug reaction to both the suspect medications.</narrativeincludeclinical>
				<reportercomment/>
				<senderdiagnosismeddraversion/>
				<senderdiagnosis/>
				<sendercomment>This patient was diagnosed with drug rash with eosinophilia and systemic symptoms (DRESS) while on acetaminophen and cefditoren therapy. Based on the nature of the event and considering the positive lymphocyte transformation test for acetaminophen and cefditoren, the event was considered a drug reaction to both the suspect medications.</sendercomment>
			</summary>
		</patient>
	</safetyreport>